Biotech company to present how biomarkers improve breast cancer risk prediction in women under hormone replacement therapy. Cambridge, Mass. – Feb. 4, 2015 – sphingotec LLC announced today that the…
SphingoTec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, today announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and…
